We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

204 hedge funds and large institutions have $3.91B invested in Ionis Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more capital invested

Capital invested by funds: $2.84B → $3.91B (+$1.07B)

18% more funds holding

Funds holding: 173204 (+31)

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

31% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $58.5M

Holders
204
Holders Change
+31
Holders Change %
+17.92%
% of All Funds
6.61%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
46
Increased
61
Reduced
75
Closed
13
Calls
$40.4M
Puts
$58.5M
Net Calls
-$18M
Net Calls Change
-$24.6M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
51
Baker Bros. Advisors
New York
$9.27M
MAA
52
Managed Account Advisors
New Jersey
$8.82M +$1.96M +65,755 +39%
California Public Employees Retirement System
53
California Public Employees Retirement System
California
$8.71M +$1.29M +43,100 +23%
UBS AM
54
UBS AM
Illinois
$8.65M +$5.4M +180,860 +365%
BIM
55
Bogle Investment Management
Massachusetts
$8.27M -$2.22M -74,216 -25%
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$7.58M +$188K +6,307 +3%
QBFM
57
QS Batterymarch Financial Management
New York
$7.43M
PA
58
Perceptive Advisors
New York
$7.24M +$5.76M +192,800 New
New York State Common Retirement Fund
59
New York State Common Retirement Fund
New York
$6.71M +$5.34M +178,600 New
GC
60
Guggenheim Capital
Illinois
$6.53M -$477K -15,984 -8%
Wellington Management Group
61
Wellington Management Group
Massachusetts
$6.26M +$3.24M +108,400 +186%
Axa
62
Axa
France
$6.22M +$1.05M +35,237 +27%
TA
63
Teachers Advisors
New York
$5.86M +$211K +7,065 +5%
Arrowstreet Capital
64
Arrowstreet Capital
Massachusetts
$5.84M +$4.65M +155,564 New
EMFAT
65
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.56M +$282K +9,440 +7%
Morgan Stanley
66
Morgan Stanley
New York
$5.47M -$28.6K -958 -0.7%
N
67
Nuveen
North Carolina
$5.28M +$1.38M +46,234 +49%
Two Sigma Investments
68
Two Sigma Investments
New York
$5.03M +$4.01M +134,081 New
RJA
69
Raymond James & Associates
Florida
$4.97M +$384K +12,869 +11%
NFA
70
Nationwide Fund Advisors
Ohio
$4.73M -$1.33M -44,442 -26%
RhumbLine Advisers
71
RhumbLine Advisers
Massachusetts
$4.44M -$12K -403 -0.3%
ProShare Advisors
72
ProShare Advisors
Maryland
$4.3M +$525K +17,563 +18%
CM
73
Castleark Management
Illinois
$4.21M +$3.24M +108,500 New
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
$3.93M
BBA
75
BLB&B Advisors
Pennsylvania
$3.84M -$17.8K -596 -0.6%

IONS Hedge Fund Activity: Q3 2013 in Review

204 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2013, worth a combined $3.91B — up 38% from $2.84B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IONS positions and 13 closed out — a net gain of 33 holders — while 61 added to existing stakes and 75 trimmed.

The largest buyer was Artisan Partners, adding an estimated $43.9M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $29.9M.

  • 204 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2013, up from 173 in Q2 2013.
  • Funds reported $3.91B of Ionis Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of +33 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2013 was Artisan Partners, an estimated $43.9M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2013.